Compare M&T Bank Corporation (MTB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs TG Therapeutics Inc — how do they compare? M&T Bank Corporation trades at $248.99 (market cap $36.15B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: M&T Bank Corporation is far larger — about 4.4× TG Therapeutics Inc's market cap, and M&T Bank Corporation pays a 2.41% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTB | TGTX | |
|---|---|---|
Market Cap | $36.15B | $8.26B |
Sector | Financials | Health |
52-Week High | $254.04 | $59.06 |
52-Week Low | $178.63 | $26.39 |
Dividend Yield | 2.41% | — |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
